Novartis partners with Orionis Biosciences on 'intractable' disease targets

Swiss pharma giant Novartis (NOVN: VX) has entered into a collaboration targeting multiple therapeutic areas with emerging biotech firm Orionis Biosciences.

Headquartered in Waltham, Massachusetts, USA, and with research operations in Belgium, Orionis has developed innovative technologies in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities to tackle the industry’s most intractable disease targets.

The goal of the four-year collaboration with Novartis is to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas, by broadly leveraging Orionis’ Allo-Glue technology platform. The terms of the collaboration include research funding, a convertible note investment, royalties and potential clinical milestones. Financial details were not disclosed.